

Contents

Introduction

Dr R G Hughes - Consultant in Pharmaceutical Development

Chapter 1

Assessing the Commercial Implications of Cardiotoxicity

**Jo Pisani and Yann Bonduelle, Pharmaceutical Strategy Consultants,
PricewaterhouseCoopers LLP**

- 1.0 Introduction
- 1.1 The cardiotoxicity challenge
- 1.2 The impact on stakeholders of cardiotoxicity
- 1.3 Assessing the size of the cardiotoxicity problem
- 1.4 Assessing the commercial costs of cardiotoxicity
- 1.5 Reacting to a cardiotoxic event: What option?
- 1.6 The case of Vioxx direct costs
- 1.7 The case of Fen-Phen: Impact on the obesity market
- 1.8 The case of Celebrex: The indirect costs of cardiotoxicity
- 1.9 The case of Vioxx & Fen-Phen: Litigation costs
- 1.10 The case of Gleevec: Reformulation costs
- 1.11 Understanding and addressing the problem of cardiotoxicity in the future
- 1.12 So what?

Chapter 2

Introduction to Cardiac Pharmacology

Professor D Terrar - Professor of Cardiac Electrophysiology, University of Oxford

- 2.0 A discussion of the pharmacology of the heart and what are the key pharmacologic processes
- 2.1 Introduction
- 2.2 Drug action and the heart
 - 2.2.1 *Ion channels and what they are and do*
 - 2.2.2 *Which enzymes and other proteins are important?*
 - 2.2.3 *Which proteins are involved in the contractile process?*

Chapter 3

Introduction to electrical activity in the heart

Professor D Terrar - Professor of Cardiac Electrophysiology, University of Oxford

- 3.0 Description of the important electrical processes
- 3.1 Equivalent circuit model
- 3.2 Electrogenic transporters and their influence on membrane potential.
- 3.3 Importance of g_{K1} and its reduction during the action potential plateau
- 3.4 Detailed models of electrical activity in ventricular myocytes
- 3.5 Genes associated with ion channels
 - 3.5.1 *Description of an electrocardiogram*

Chapter 4

Mechanisms of Cardiac Toxicity

Professor D Terrar - Professor of Cardiac Electrophysiology, University of Oxford

- 4.0 QT interval prolongation
- 4.1 QT interval shortening
 - 4.1.1 *Torsade des Pointes*
 - 4.1.2 *Short and long term functional changes*
 - 4.1.3 *Gene related adverse events*

Chapter 5

Preclinical Determination of Cardiac Toxicity

Professor D Terrar - Professor of Cardiac Electrophysiology, University of Oxford

- 5.0 *In Vitro*
- 5.1 hERG testing
 - 5.1.1 *Advantages of hERG assays*
 - 5.1.2 *Conventional electrophysiology*
 - 5.1.3 *High throughput methods*
 - 5.1.4 *Disadvantages of hERG assays*
- 5.2 Purkinje Fibres
 - 5.2.1 *Myocytes (action potentials and currents)*
 - 5.2.2 *Papillary muscles*
 - 5.2.3 *Langendorf Hearts*
 - 5.2.4 *Cardiac Wedge*
- 5.3 *In vivo* telemetry

Chapter 6

Determination of Cardiac Toxicity in the Clinic

Daniel B. Goodman, MD, Medical Director, Entelligent Solutions, Inc
Eileen M. Daniel, Vice President of Operations, Reliance Clinical Research Services

- 6.0 Introduction
- 6.1 Early Phase Clinical Trials
 - 6.1.1 *Thorough QT/QTc Study*
 - 6.1.2 *TQTS Design*
 - 6.1.3 *The TQTS in Practice*
 - 6.1.4 *Collection of ECG data in the Clinic*
 - 6.1.5 *Completion of ECG readings*
 - 6.1.6 *Clinical Study Report*
- 6.2 Later Phase Trials
 - 6.2.1 *Oncology*
 - 6.2.2 *Other Cardiac Toxicity*
- 6.3 Conclusion

Chapter 7

Regulatory Aspects of QT/QTc Interval Prolongation

Thomas E. Donnelly, Ph.D., Senior Vice President of Regulatory Affairs, Quality Assurance and Compliance, Reliance Clinical Research Services

- 7.0 Introduction
- 7.1 ICH Guidance and Thorough QT (TQT) Study
- 7.2 Risk Management Guidance during Development
- 7.3 Regulatory Review of QT/QTc Protocols
- 7.4 Interdisciplinary Review Team for QT Studies
- 7.5 Risk Management Guidance Post-Marketing for Drugs that Prolong the QT/QTc Interval
 - 7.5.1 *Risk Management General*
 - 7.5.2 *Risk Management with QT/QTc Interval Prolongation*
- 7.6 Labeling Issues for Drugs that Prolong the QT/QTc Interval
- 7.7 Regulatory Review of Clinical Safety Data in a Marketing Application
- 7.8 Summary

Chapter 8

Future Prospects

Professor D Terrar
Dr Eileen Daniel
Dr D Goodman
Dr T Donnelly
Dr RG Hughes

- 8.0 Imaging: Optical probes for measuring electrical activity
- 8.1 Imaging: Optical probes for calcium and other ions
- 8.2 Tissue culture cardiac cells
- 8.3 Computational methods
- 8.4 Medium Throughput screening for cardiac toxicity
- 8.5 Commercial prospects
- 8.6 Regulatory prospects
- 8.7 Clinical Challenges

Chapter 9

References and Useful Reading

Chapter 10

Glossary & Abbreviations

About the Contributors